Streetbeat News

ISEE

IVERIC bio Inc

https://ivericbio.com/

CEO

Glenn Sblendorio

Employees

205

Industry

Pharmaceutical Preparation Manufacturing

we are a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (amd).

Open

39.86

Mkt cap

5.5B

Volume

11M

High

39.98

P/E Ratio

-22.44

52-wk high

39.99

Low

39.85

Div yield

N/A

52-wk low

9.39

Goldman Sachs research suggests the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This comes as patents for some blockbuster drugs are nearing expiration. Recent examples include Astellas Pharma acquiring Iveric Bio, Pfizer proposing to acquire Seagen, GSK agreeing to acquire BELLUS Health, and Merck announcing to acquire Prometheus Biosciences. The healthcare sector had a challenging start to 2023 due to regulatory & growth concerns, macroeconomic rotations, and investor preference for large-cap technology stocks.

Portfolio Pulse from Vandana Singh

July 07, 2023 | 5:18 pm

Iveric Bio Inc's board of directors has approved a merger proposal with Astellas Pharma at a special meeting held on July 6.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 5:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.